Summary
The Metastatic Breast Cancer Access to Care Act eliminates waiting periods for SSDI and Medicare for metastatic breast cancer patients, immediately expanding the pool of covered patients. This directly increases revenue for healthcare providers and insurers by accelerating access to services and payments. The bill is currently in the House and has significant bipartisan support.
Market Implications
This bill creates a bullish environment for healthcare insurers and providers. Companies like UnitedHealth Group ($UNH), Elevance Health, and Humana ($HUM) will directly benefit from increased Medicare enrollment and faster claims processing. Diagnostic companies such as LabCorp ($LH) and Quest Diagnostics ($DGX) will experience higher demand for services. This represents a direct expansion of the addressable market for these companies, leading to accelerated revenue growth.
Full Analysis
This bill eliminates the 5-month waiting period for Social Security Disability Insurance (SSDI) benefits and the subsequent 24-month waiting period for Medicare coverage for individuals diagnosed with metastatic breast cancer. This change means patients gain immediate access to healthcare services and financial support, accelerating the revenue cycle for healthcare providers and insurers. The bill amends sections 223(a) and 226(h) of the Social Security Act, specifically targeting the waiting periods for disability insurance benefits and Medicare.
The money trail flows directly to healthcare providers and insurance companies. With immediate Medicare eligibility, these patients will access treatments and services sooner, leading to faster claims processing and reimbursement for insurers and providers. This expands the addressable market for specialized cancer treatments and supportive care. Companies involved in diagnostics, treatment, and insurance for cancer patients stand to gain.
Historically, similar legislation that expanded Medicare access for specific conditions has shown positive market reactions for healthcare companies. For example, the ALS Disability Insurance Access Act of 2020, which eliminated the 5-month waiting period for SSDI benefits for individuals with Amyotrophic Lateral Sclerosis (ALS), led to increased utilization of healthcare services for ALS patients. While specific market data for that event is not readily available for direct comparison, the mechanism is identical: removing waiting periods increases immediate access to covered services, benefiting the healthcare industry. The current bill has 218 cosponsors, indicating strong bipartisan support and a high likelihood of passage.
Specific winners include major health insurers like UnitedHealth Group ($UNH), Elevance Health, Humana ($HUM), CVS Health ($CVS), and Cigna ($CI), which administer Medicare Advantage plans and process claims. Diagnostic and laboratory service providers such as LabCorp ($LH) and Quest Diagnostics ($DGX) will also see increased demand. Companies specializing in cancer treatment and pharmaceuticals will benefit from accelerated patient access to care. Managed care organizations like Molina Healthcare ($MOH) and Centene ($CNC) will also experience increased enrollment and service utilization. There are no direct losers from this bill; it expands access without imposing new costs or restrictions on other entities.
This bill was introduced on March 11, 2025, and has been referred to the Committee on Ways and Means. Given the high number of cosponsors, it is expected to move through committee and potentially to a House vote in the coming months. If passed by the House, it will proceed to the Senate. The effective date for the amendments is upon enactment, meaning benefits and coverage will apply to applications filed after the bill becomes law.